In Reply We thank Liede and colleagues for their insightful comments and for the opportunity to clarify our work. The purpose of our study1 was to determine the incidence of breast cancer in BRCA-positive patients who received a diagnosis of ovarian cancer and to discuss the role of breast cancer imaging surveillance for this high-risk group. In our study,1 8.9% of patients with a BRCA mutation developed breast cancer after receiving a diagnosis of ovarian cancer (an incidence similar to that found by Domchek et al2), with less than 10% of patients with ovarian cancer subsequently receiving a diagnosis of breast cancer. A significant proportion of our patients (41%) died of ovarian cancer that recurred within 3 years of initial diagnosis. Furthermore, a majority of our patients presented with at least stage IIIC or IV ovarian cancer, which confers a worse prognosis.
Gangi A, Baramparas G, Amersi FF. Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers—Reply. JAMA Surg. 2015;150(5):491–492. doi:10.1001/jamasurg.2015.0196
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: